Emla-Cream as Pain Relief During Pneumococcal Vaccination

• Status: Recruiting
• Trial end date: 2021-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this intervention study is to compare the efficacy of Emla cream as a pain relief or no pain relief in connection to the first pneumococcal vaccination at the age of three months in Child health care.

Primary objective

1.Leads Emla cream as pain relief to children in connection with pneumococcal vaccination at the age of three months to lower pain scores in the use of FLACC as a pain measurement instrument?

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beatrice Olsson Duse
• Treatments: EMLA; Lidocaine; Lidocaine, Prilocaine Drug Combination; Prilocaine; Vaccines

Criteria

Inclusion Criteria:

• Healthy children, born vaginally or by cesarean section after 37 weeks of gestation, who were not admitted to the neonatal unit. Children should only have been with the PKU testing performed routinely at the hospital.

Exclusion Criteria:

• Baby delivered by vacuum extraction or forceps. Children born before gestational week

37. Children in neonatal care and subjected to other testing than PKU. Shoulder dystocia. Children susceptible to methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia. Children with atopic dermatitis.